Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
Cancer is one of the most difficult diseases to treat. It is constantly changing, ...
Cancer is one of the most difficult diseases to...
ââOrthofix Medical Inc. is a diversified, global medical device company focuse...
ââOrthofix Medical Inc. is a diversified, g...
Galectin Therapeutics is a biotechnology company focused on discovery and developm...
Galectin Therapeutics is a biotechnology compan...
LifeBridge 10000, LLC specializes in extending and improving the quality of life f...
LifeBridge 10000, LLC specializes in extending ...
TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed...
TherapeuticsMD, Inc. is an innovative pharmaceu...
Since the companyâs inception, Tetraphase has developed a robust antibiotics pla...
Since the companyâs inception, Tetraphase has...
Compugen is a drug discovery company with a unique, broadly applicable, predictive...
Compugen is a drug discovery company with a uni...
Join the National Investor Network and get the latest information with your interests in mind.